Evidence-based Anticancer Materia Medica, William C.S. Cho

Автор: Thurston
Название: Chemistry and Pharmacology of Anticancer Drugs, Second Edition
ISBN: 1439853266 ISBN-13(EAN): 9781439853269
Издательство: Taylor&Francis
Рейтинг:
Цена: 19906.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: This book is a comprehensive survey of all families of anticancer agents and therapeutic approaches. The book will acts as an indispensable resource for researchers, medicinal chemists and biomedical scientists. The new edition of this book will also have a Companion Website.

Автор: William C.S. Cho
Название: Materia Medica for Various Cancers
ISBN: 9400737408 ISBN-13(EAN): 9789400737402
Издательство: Springer
Рейтинг:
Цена: 28732.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: This volume presents the experimental and clinical evidence of anticancer materia medica for various cancers. The text provides concise reviews and expert opinions on the recent progress of materia medica research in fourteen particular cancers, from bench to bedside application.

Автор: Missailidis
Название: Anticancer Therapeutics
ISBN: 0470723033 ISBN-13(EAN): 9780470723036
Издательство: Wiley
Рейтинг:
Цена: 24386.00 р.
Наличие на складе: Поставка под заказ.

Описание: Written by the winner of the 2008 Mike Price Fellowship The need to re-address known anti-cancer agents and discover new ones are of paramount importance. Anticancer Therapeutics provides a comprehensive overview of the wealth of information currently available on this important and fast-moving subject.

Автор: Teicher
Название: Anticancer Drug Development Guide. 2ed.2004
ISBN: 1588292282 ISBN-13(EAN): 9781588292285
Издательство: Springer
Рейтинг:
Цена: 34799.00 р.
Наличие на складе: Есть у поставщика Поставка под заказ.

Описание: This thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey provides a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, working with the NCI, and the FDA's role in cancer drug development and setting requirements for approval.